Hörsch D, Sayeg Y, Bonnet R, Kaemmerer D, Presselt N, Baum R P
Zentrum für Neuroendokrine Tumore Bad Berka–ENETS Center of Excellence und Klinik für Innere Medizin, Gastroenterologie und Endokrinologie, Deutschland.
Pneumologie. 2012 Jan;66(1):44-8. doi: 10.1055/s-0031-1291478. Epub 2012 Jan 16.
Neuroendocrine tumours of the lung exhibit an increasing incidence and prevalence. However, data on the diagnosis of and therapy for these tumours are sparse compared to neuroendocrine tumours of the gastroenteropancreatic system.
The present article reflects a dialogue between experts on neuroendocrine tumors of the lung and the gastroenteropancreatic system held on February 25th and 26th in Weimar, Germany.
Many similarities exist between neuroendocrine tumours of the lung and the gastroenteropancreatic system but there are also significant differences. Similarities exist mainly concerning pathology, diagnosis and therapy. Differences exist regarding the systemic therapy and the significantly lower incidence of paraneoplastic syndromes. Somatostatin receptor PET/CT with gallium-68 labelled somatostatin analogues and peptide receptor radiotherapy are innovative methods for the diagnosis of and therapy for neuroendocrine tumours of the lung. The first treatment option remains complete resection of the tumour. Small molecules like everolimus (Afinitor®) have been tested in clinical trials and have been shown to prolong progression-free survival.
Additional studies are necessary and efforts should be undertaken to establish a registry to increase data on methods suitable for he diagnosis of and therapy for neuroendocrine tumours of the lung.
肺神经内分泌肿瘤的发病率和患病率呈上升趋势。然而，与胃肠胰系统神经内分泌肿瘤相比，关于这些肿瘤诊断和治疗的数据较少。
本文反映了2月25日和26日在德国魏玛举行的肺神经内分泌肿瘤专家与胃肠胰系统神经内分泌肿瘤专家之间的对话。
肺神经内分泌肿瘤与胃肠胰系统神经内分泌肿瘤之间存在许多相似之处，但也存在显著差异。相似之处主要体现在病理、诊断和治疗方面。差异在于全身治疗以及副肿瘤综合征的发生率显著较低。使用68Ga标记的生长抑素类似物的生长抑素受体PET/CT和肽受体放射治疗是肺神经内分泌肿瘤诊断和治疗的创新方法。首要治疗选择仍然是肿瘤的完全切除。像依维莫司（飞尼妥®）这样的小分子已在临床试验中进行了测试，并已证明可延长无进展生存期。
需要进行更多研究，并应努力建立一个登记处，以增加适用于肺神经内分泌肿瘤诊断和治疗方法的数据。
